INTRODUCTION
Dextropropoxyphene (DXP) has been one of the most widely prescribed and used analgesics in the world, specifically in France since the beginning of marketing in 1964 (more than 70 million packages sold per year) [1] [2] [3] . This drug was particularly prescribed in the elderly, as reported by a health and social welfare survey (ESPS) performed in 2000, showing that DiAntalvic® represented the largest drug item consumed by patients over 65 years old [4] [5] [6] .
This opiate was indicated for the treatment of low to moderate intensity pain [3, 7] . In France, more than thirty specialties contained DXP, most often in association with paracetamol (DXP/PC) [1, 7] . Recommendations regarding therapeutic alternatives for DXP were produced by the National Agency for drugs and health products safety (the Afssaps, later renamed the ANSM) in collaboration with its general practitioners reference group, the French Society for the Study and Treatment of Pain (SFETD) and the French Society of Rheumatology (SFR) [12] .
However, prescriber's concerns regarding the safety of these alternative analgesics, mainly tramadol, and regarding patient compliance with recommendations, may have affected DXP/PC substitution mechanisms, and subsequently the management of pain in France with impacts on public health.
To identify the therapeutic alternatives prescribed by anaesthesiologists and pain specialists after DXP withdrawal, a survey was conducted among Sfar and SFETD members. The second objective of the survey was to obtain physician feedback regarding the withdrawal of a popular drug in France, particularly as concerns the elderly.
METHODOLOGY

Surveys of two Learned Societies involved in pain management
A survey regarding DXP withdrawal targeted anaesthesiologist members of the French Society of Anaesthesia and Intensive Care Medicine active in secondary care (public and private hospitals), albeit not consulting for chronic pain. This survey (11 questions) was accessible on the www.sfar.org website (Appendix 1).
For SFETD members, a slightly different survey was provided to pain specialists active either in secondary care, or in centres for pain evaluation and treatment (CETD). This survey (15 questions) was available on the www.sfetd-douleur.org website (Appendix 2).
Survey Monkey® software was used to create the survey. Overall, 3000 SFARanaesthesiologists and 911 SFETD-pain specialists received a link to the surveys by mail. In the absence of reply after 2 months, two reminders were sent by email. Answers were anonymised before processing the data.
Survey processing
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The two surveys were confidential and anonymous, and their final version was validated by the regional anaesthesia and pain committee and the administrative councils of both the SFAR and the SFETD. They were conducted between December 2012 and March 2013. SFAR and SFETD physicians were informed by email that a link was available to access a survey focused on DXP.
The survey questions assessed physician gender and age, work place and status, DXP prescribing uses before withdrawal, feedback regarding withdrawal and prescribing patterns after withdrawal. In addition to these questions, algologists had to provide detailed information on DXP prescribing before withdrawal (target populations, prescribing frequency, targeted pain intensity and indications).
Data analysis
Data were entered on EXCEL® sheets. Results were descriptive and presented as percentages. When applicable (comparison of results from different lines of activity), a 2 test was applied. The significance threshold was set to 5%. All analyses were performed using STATVIEW® software.
RESULTS
A total of 697 questionnaires were analysed, comprising 433 SFAR and 234 SFETD questionnaires. The Sfar and SFETD participation rates were 14.3% and 25.7 %, respectively.
The general characteristics of surveyed physicians are presented in Table I .
DXP prescribing uses before withdrawal: population? Types of pain?
Before withdrawal, DXP was prescribed by 72.7% of anaesthesiologists and 80.6% of pain specialists. Both specialties prescribed this drug for pain of moderate intensity (Figure 1 ). 
DXP replacement procedures
Physicians were surveyed about their personal DXP alternative strategies, if applicable. In This survey was the first to evaluate the opinion of two pain specialist populations regarding DXP withdrawal and its consequences in terms of therapeutic alternatives. According to prescribing data collected in 2006 by DOREMA surveys (Documentation and marketing research), the DXP-PC combination was then mainly prescribed to treat lumbago and arthrosis. The mean posology was 4.6 tablets per day for a mean treatment duration of 30.8 days [18] .
While almost two thirds of pain specialists felt concerned by the DXP withdrawal, this event did not have a significant impact on anaesthesiologists' habits. In both groups, the main substitution analgesic was tramadol associated with paracetamol, while paracetamol alone was used in 24% of cases. Hawton et al. [19] analysed the consequences in terms of morbidity or mortality and substitution, 6 years following DXP-PC withdrawal in Britain. Prescriptions of tramadol and paracetamol increased by 19% and 16% respectively, mainly in favour of a codeine-paracetamol association (+23%). By contrast, in France, in an Academic Hospital, a study performed before the national DXP withdrawal showed that DXP withdrawal induced a 4.6% decrease in total analgesic consumption with a specific 28% reduction of level II drugs (increase of tramadol and decrease of the codeine-paracetamol association). During the same period, non-morphine analgesics showed an 11% increase, while consumption of morphine and related compounds decreased by 8% [15] . Due to the strong support from local teams involved in analgesia, the consequences of withdrawal were nonetheless different than those observed at the national or European scales [15, 19] . Regarding the effects of DXP withdrawal on the effectiveness of pain management, Becquemont and al. analysed the consequences of withdrawal on elderly patients suffering from chronic pain. While tramadol (mainly), paracetamol, codeine and opium were the main therapeutic alternatives in this study, no consequence in terms of pain intensity, comfort or quality of life was found [20] .
In our survey, most anaesthesiologists expressed satisfaction regarding the effects of DXP.
They did not consider DXP to be dangerous nor ineffective. Nonetheless, the majority of health care professionals who did not prescribe DXP explained their attitude by pointing out the dangerousness and lack of efficacy of DXP. It is then paradoxical that the withdrawal was more accepted by anaesthesiologists than by pain specialists, the majority of whom did not follow the ANSM's recommendations. Nevertheless, the benefit/risk ratio was evaluated by DXP non-prescribers while withdrawal feedback was estimated by the whole group of physicians surveyed.
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In terms of replacement therapy, the Afssaps (ANSM) recommended tramadol/paracetamol and codeine/paracetamol, and to a lesser extent, paracetamol alone. While this switch was observed for pain specialists, it was independent of AFSSAPS recommendations that both groups largely ignored. It would then be of interest to investigate the determinants of physician's choice of replacement therapy, as there was no major difference between the groups regarding the distribution of alternative choices. Only the opium-paracetamol combination (Lamaline®) was more prescribed by pain specialists than by anaesthesiologists, where the prescription rate was only 6%.
This study has certain limitations. A declarative survey was used, and the quality of the information reported by the interviewed prescribers was not validated. Therefore, the data collected cannot be controlled. Moreover, the participation rate was low and the results may not be representative of the opinion of all anaesthesiologists and pain specialists at the national level. Finally, this study did not collect information on the consequences of substitution therapy in terms of substitutive drugs; it did not detail prescribed doses and patterns of use, nor compliance with marketing authorization.
In summary, 18 months following the DXP-paracetamol withdrawal, a survey was conducted among two prescriber populations: anaesthesiologists (SFAR) and pain specialists (SFETD).
The survey confirmed the important place occupied by this drug, mainly prescribed for moderate pain, particularly in outpatient surgery and for articular pain. Substitutive analgesics were represented by tramadol, mainly associated with paracetamol, but also by codeineparacetamol, while paracetamol alone represented only 24% of all prescriptions. A specific analysis of national NHS claims data would be of major interest to confirm the substitutive strategies declared by surveyed physicians, and to follow a cohort of patients who used DXPparacetamol for several years in order to identify substitutive analgesics and their effects.
Indeed, France was the major DXP-paracetamol user in Europe with almost 8 million consumers. It would be highly relevant to track such patients and to evaluate the clinical and economic consequences of DXP withdrawal, notably in terms of morbidity linked to substitute analgesics consumption.
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We would like to thank the members of the Sfar ALR pain committee, the Sfar administration council for providing authorization and access to the SFAR database, and the SFETD administration council for providing authorization and access to the SFETD database. M a n u s c r i p t 10 Besides the risk of overdose, it is necessary to highlight the fact that a sudden discontinuation of a chronic treatment DXP could lead, as for any morphinic-like drug, to a withdrawal syndrome with very serious consequences. The procedure for DXP substitution by another drug, or for drug discontinuation, had therefore to be applied very carefully, according to December 2010 recommendations, even if these recommendations were very theoretical.
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The main goal of this survey is to determine and identify the therapeutic alternatives prescribed by the three specialties most involved in acute and chronic pain management, particularly by dedicated pain physicians.
Indeed, it is of high relevance to known whether prescribers have chosen to substitute DXP by an analgesic of similar level, increased or decreased their prescription level, or suppressed the treatment without replacement.
Never before has such a highly prescribed drug been suppressed from the French pharmacopeia.
The secondary objective was to evaluate physician feedback regarding this withdrawal. It should also imply knowledge of the drug prescription pattern before its withdrawal. 
